VBIO
Valion Bio, Inc.
There isn't enough reported data to score VBIO yet.
VBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
VBIO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
VBIO PE Valuation
VBIO has no meaningful PE right now: it lost money over the past year.
VBIO Forward outlook
There aren't enough analyst estimates for VBIO to show an outlook.
VBIO Earnings Per Share
VBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $146K | +16% |
| Q2 2025 | $86K | -39% |
| Q1 2025 | $70K | -79% |
| Q4 2024 | $180K | -50% |
| Q3 2024 | $126K | -55% |
| Q2 2024 | $140K | -13% |
| Q1 2024 | $334K | -11% |
| Q4 2023 | $357K | -13% |
VBIO's revenue is recovering but still below its 2022 peak: $146,000 last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1701% | -565 points |
| Q2 2025 | -2249% | -1387 points |
| Q1 2025 | -2151% | -1708 points |
| Q4 2024 | -857% | -229 points |
| Q3 2024 | -1136% | -512 points |
| Q2 2024 | -861% | +459 points |
| Q1 2024 | -443% | +119 points |
| Q4 2023 | -629% | -76 points |
VBIO's operating margin was −1701% last quarter, down 565 points from the same quarter a year ago, near the bottom of its range since 2020.
VBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$5M | -$4.1M |
| Q4 2023 | -$1.8M | +$453K |
| Q3 2023 | -$1.9M | +$906K |
| Q4 2022 | -$2.2M | +$533K |
| Q3 2022 | -$2.8M | -$1.1M |
| Q4 2021 | -$2.8M | -$2.2M |
| Q3 2021 | -$1.6M | -$1.1M |
| Q2 2021 | -$543K | +$115K |
VBIO has burned cash in almost every quarter: −$15M over the past year, against −$7M the year before.
VBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +19.9K shares |
| 1 year | +467% | +111K shares |
VBIO has 135,200 diluted shares, up 467% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VBIO Net Leverage
VBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.0 | Oversold |
| Stochastic | 0.1 | Oversold |
VBIO's weekly RSI is 22 (oversold) and its Stochastic is 0 (oversold).
VBIO PE vs Healthcare Sector
VBIO has no meaningful PE right now: it lost money over the past year.
VBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 64% below |
| 20 week MA | $4.48 | 89% below |
| 50 week MA | $17.8 | 97% below |
VBIO is in a downtrend: it's below all three of its weekly moving averages, and 97% below its 50-week average.
VBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $93.0 | $40.3 | -57% |
| 2026 YTD | $40.3 | $0.51 | -99% |
VBIO has finished every year since 2025 lower, and it's down 99% so far in 2026.